BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its primary endpoint
April 6 Kyowa Hakko Kirin Co Ltd:
* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint
* Kyowa Hakko Kirin Co Ltd -plans to initiate discussions with global regulatory authorities in 2017 Source text:(bit.ly/2p7esaz) Further company coverage:
UPDATE 4-North Korea tests rocket engine, possibly for ICBM - U.S. officials
* S.Korea's Moon says engagement must be backed by strong defense
GLOBAL MARKETS-Tentative oil price recovery lifts energy stocks
LONDON, June 23 World stocks were poised to eke out slim gains for the week on Friday as a tentative recovery in oil prices spurred investors to hunt for bargains in the beaten-down energy sector and helped commodity-related currencies gain against the dollar.